We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

75 hedge funds and large institutions have $180M invested in Viracta Therapeutics, Inc. Common Stock in 2013 Q2 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

92% less call options, than puts

Call options by funds: $209K | Put options by funds: $2.58M

Holders
75
Holders Change
+75
Holders Change %
–
% of All Funds
2.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
75
Increased
–
Reduced
–
Closed
–
Calls
$209K
Puts
$2.58M
Net Calls
-$2.37M
Net Calls Change
-$2.37M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$31.3M +$31.9M +28,625 New
NMC
2
NEA Management Company
Maryland
$29.3M +$29.9M +26,841 New
RCM
3
RA Capital Management
Massachusetts
$24.5M +$25M +22,459 New
VAM
4
Visium Asset Management
New York
$21.2M +$21.6M +19,396 New
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$8.57M +$8.73M +7,838 New
BA
6
BlackRock Advisors
Delaware
$8.1M +$8.29M +7,437 New
Millennium Management
7
Millennium Management
New York
$7.33M +$7.5M +6,734 New
Bank of New York Mellon
8
Bank of New York Mellon
New York
$6.83M +$6.99M +6,271 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$4.96M +$5.05M +4,533 New
BFA
10
BlackRock Fund Advisors
California
$4.18M +$4.28M +3,841 New
UBS AM
11
UBS AM
Illinois
$3.15M +$3.21M +2,878 New
FCM
12
Farallon Capital Management
California
$2.48M +$2.52M +2,262 New
BIT
13
BlackRock Institutional Trust
California
$2.33M +$2.39M +2,143 New
State Street
14
State Street
Massachusetts
$2.22M +$2.26M +2,029 New
Northern Trust
15
Northern Trust
Illinois
$2.16M +$2.21M +1,984 New
DCM
16
Driehaus Capital Management
Illinois
$1.51M +$1.54M +1,385 New
EI
17
EAM Investors
California
$1.43M +$1.46M +1,307 New
SGAM
18
Smith Group Asset Management
Texas
$1.23M +$1.26M +1,134 New
U
19
UBS
Switzerland
$1.1M +$1.13M +1,015 New
Wellington Management Group
20
Wellington Management Group
Massachusetts
$1.09M +$1.11M +994 New
SM
21
Sabby Management
Florida
$939K +$957K +859 New
Adage Capital Partners
22
Adage Capital Partners
Massachusetts
$778K +$796K +714 New
GACM
23
Green Arrow Capital Management
New York
$778K +$796K +714 New
Geode Capital Management
24
Geode Capital Management
Massachusetts
$713K +$725K +651 New
PCA
25
Private Capital Advisors
Connecticut
$654K +$669K +600 New
1
2 3

VIRX Hedge Fund Activity: Q2 2013 in Review

75 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2013, worth a combined $180M.

Buyers outnumbered sellers: 75 funds opened new VIRX positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.

  • 75 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $180M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2013.
  • 75 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2013 and 0 closed out, a net change of +75 holders.

Based on aggregated 13F filings for Q2 2013.